Background: 1% of all cancers and about 10% of all
haematologic malignancies are multiple myeloma (MM).
In various human cancers, including multiple myeloma,
abnormal expression or deregulation of JAM-A, which
controls cell growth and differentiation, results in a more
aggressive phenotype and poor prognosis. Aim: to
evaluate the immunohistochemical expression of JAM-A
in cases of multiple myeloma and correlate its expression
with variable clinicopathological parameters to assess its
possible diagnostic and prognostic role and hence
therapeutic modalities. Material and method: This is a
selected retrospective immunohistochemical study of
JAM-A performed on 40 cases of MM. Results: There is
a statistically significant direct correlation between JAMA overexpression and older Age (P= .022), histological
type (immature & plasmablastic)(P=.020), diffuse pattern
of infiltration(P=.016), increased BMB
cellularity(P=.017), higher ISS Stage (P=.033), advanced
R- ISS Stage (P=.042), No Complete response(P=.008),
more Resistance to therapy (P= .032), Karyotyping result
(P=.019), short survival (P= .014). Conclusion: JAM-A overexpression might have
an important role in proliferation, invasion, progression, poor outcome of multiple
myeloma cases. So, JAM-A might have a promising value in treatment of MM.